Expression of Bcl-2 in Adult Human Brain Regions with Special Reference to Neurodegenerative Disorders |
| |
Authors: | Sheela Vyas,France Javoy-Agid,Marí a-Trinidad Herrero,Ornella Strada,Florence Boissiere,&dagger Urzula Hibner, Yves Agid |
| |
Affiliation: | INSERM U. 289, CHU Pitié-Salpêtrière, Paris;; IGM, CNRS, Montpellier, France;and; Departamento de Ciencias Morfológicas, Facultad de Medicina, Universidad de Murcia, Murcia, Spain |
| |
Abstract: | Abstract: The expression of the protooncogene bcl-2 , an inhibitor of apoptosis in various cells, was examined in the adult human brain. Several experimental criteria were used to verify its presence; mRNA was analyzed by northern blot with parallel experiments in mouse tissues, by RNase protection, and by in situ hybridization histochemistry. Bcl-2 protein was detected by western blot analysis and immunohistochemistry. Two bcl-2 mRNA species were identified in the human brain. The pattern of distribution of bcl-2 mRNA at the cellular level showed labeling in neurons but not glia. The in situ hybridization signal was stronger in the pyramidal neurons of the cerebral cortex and in the cholinergic neurons of the nucleus basalis of Meynert than in the Purkinje neurons of the cerebellum. Both melanized and nonmelanized neurons were labeled in the substantia nigra. In the striatum, bcl-2 mRNA was detected in some but not all neurons. In the regions examined for Bcl-2 protein, the expression pattern correlated with the mRNA results. In patients with Alzheimer's and Parkinson's diseases, quantification of bcl-2 mRNA in the nucleus basalis of Meynert and substantia nigra, respectively, showed that the expression was unaltered compared with controls, raising the possibility that the expression of other components of apoptosis is modulated. |
| |
Keywords: | bcl-2 protooncogene Human brain Apoptosis Neurons Alzheimer's disease Parkinson's disease |
|
|